BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1

Approximately half of all melanoma patients harbour activating mutations in the serine/threonine kinase BRAF. This is the basis for one of the main treatment strategies for this tumor type, the targeted therapy with BRAF and MEK inhibitors. While the initial responsiveness to these drugs is high, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimm, Johannes, Hufnagel, Anita, Wobser, Marion, Borst, Andreas, Haferkamp, Sebastian, Houben, Roland, Meierjohann, Svenja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147791/
https://www.ncbi.nlm.nih.gov/pubmed/30237393
http://dx.doi.org/10.1038/s41389-018-0082-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147791/
https://www.ncbi.nlm.nih.gov/pubmed/30237393
http://dx.doi.org/10.1038/s41389-018-0082-2

Ejemplares similares